Oxford BioTherapeutics (OBT)

Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers

Appointment Follows Recent Recruitment of Senior Antibody Industry Leaders and Highlights OBT's Growth Into a Leading Oncology-Focused Therapeutic Antibody Company

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

OXFORD, England, January 25, 2011 - Oxford BioTherapeutics (OBT) today announces that sanofi-aventis has acquired an exclusive world-wide license to one of OBT's internal preclinical antibody programs.

MORE..

OXFORD, England, December 9 - Oxford BioTherapeutics (OBT) has today announced the appointment of Dr Michael Moore as non-executive Chairman.

MORE..

Older News

OXFORD, England - New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

MORE..